Floatz logo

Relatlimab

Neoplasms by Site

Bristol-Myers Squibbmonoclonal_antibodyPhase 2Active
BB
68/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
55/ 100
Competitive Position
89/ 100

Competitive context

927 Active assets in the Neoplasms by Site cohort.

Asset / SponsorPhaseRating
PANITUMUMAB
Astellas Pharma Inc
Phase 2BBB
GRANULOCYTE COLONY-STIMULATING FACTOR LENOGRASTIM
Sanofi
Phase 4BB
Glycopyrrolate
Medical College of Wisconsin
Phase 4BB
DINITROGEN MONOXIDE
Medical College of Wisconsin
Phase 4BB
Vinorelbine
Shi Yanxia
Phase 3BB

View all 50 →

Same molecule, other indications

Relatlimab is also rated in:

cutaneous melanomaDormant
BB
Indicative ·
66 / 100
View asset →
metastatic melanomaDormant
BB
Indicative ·
66 / 100
View asset →
urethra transitional cell carcinomaDormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →